A Cost-Effectiveness Analysis of First Trimester Non-Invasive Prenatal Screening for Fetal Trisomies in the United States

Brandon S. Walker1, Richard E. Nelson2, Brian R. Jackson3, David G. Grenache3, Edward R. Ashwood4, Robert L. Schmidt4*

1 ARUP Laboratories, Salt Lake City, Utah, United States of America, 2 Department of Internal Medicine, Division of Epidemiology, University of Utah, Salt Lake City, Utah, United States of America, 3 Department of Pathology and ARUP Laboratories, Salt Lake City, Utah, United States of America, 4 Department of Pathology and ARUP Laboratories, University of Utah, Salt Lake City, Utah, United States of America

* Robert.Schmidt@hsc.utah.edu

Abstract

Background

Non-invasive prenatal testing (NIPT) is a relatively new technology for diagnosis of fetal aneuploidies. NIPT is more accurate than conventional maternal serum screening (MSS) but is also more costly. Contingent NIPT may provide a cost-effective alternative to universal NIPT screening. Contingent screening used a two-stage process in which risk is assessed by MSS in the first stage and, based on a risk cutoff, high-risk pregnancies are referred for NIPT. The objective of this study was to (1) determine the optimum MSS risk cutoff for contingent NIPT and (2) compare the cost effectiveness of optimized contingent NIPT to universal NIPT and conventional MSS.

Study Design

Decision-analytic model using micro-simulation and probabilistic sensitivity analysis. We evaluated cost effectiveness from three perspectives: societal, governmental, and payer.

Results

From a societal perspective, universal NIPT dominated both contingent NIPT and MSS. From a government and payer perspective, contingent NIPT dominated MSS. Compared to contingent NIPT, adopting a universal NIPT would cost $203,088 for each additional case detected from a government perspective and $263,922 for each additional case detected from a payer perspective.

Conclusions

From a societal perspective, universal NIPT is a cost-effective alternative to MSS and contingent NIPT. When viewed from narrower perspectives, contingent NIPT is less costly than universal NIPT and provides a cost-effective alternative to MSS.
Introduction

Non-invasive prenatal testing (NIPT) is a relatively new screening method that provides greater prenatal detection of aneuploidies than conventional maternal serum screening (MSS). Clinical trial results show that NIPT is both sensitive and specific. For trisomy 21 (Down syndrome), NIPT has a sensitivity (detection rate) and specificity of approximately 99%.[1] Thus, NIPT provides high accuracy without the risk associated with invasive diagnostic testing (amniocentesis, chorionic villus sampling). NIPT can provide results as early as the 10th week of pregnancy.

Although NIPT is more accurate than MSS, it is also costly. Current list prices range from $500 to $2100 per test.[2,3] Despite the cost, studies have shown that universal NIPT screening (i.e., replacement of MSS by NIPT) is cost effective when viewed from a societal perspective.[4] Although the societal perspective is preferred for theoretical reasons, most decision makers actually use narrower perspectives such as governmental or payer perspective. Universal NIPT is not cost effective when viewed from these narrower perspectives.[4] NIPT-based screening policies might be acceptable if NIPT were used in a select subset of pregnancies rather than applied universally. Indeed, studies have shown that the selective use of NIPT among higher risk women (contingent NIPT) is less costly than universal NIPT.[5,6]

Contingent NIPT policies use a two-stage screening strategy. In the first stage, MSS is used to estimate the probability of an affected pregnancy. A pregnancy is categorized as “high risk” based on a risk threshold. Patients are referred for NIPT only if the probability of an affected pregnancy is greater than the risk threshold. Therefore, NIPT is contingent upon the results of the primary screen.

Contingent NIPT strategies are less costly than universal NIPT screening because a relatively small subset of “high-risk” patients are referred for NIPT testing.[5–7] Contingent NIPT screening policies can achieve higher detection rates than MSS by using lower risk cutoffs in the first stage. Lowering the risk cutoff in the first stage increases the number of cases classified as “high risk” so that a greater percentage of cases are referred to NIPT testing. Lowering the risk cutoff increases sensitivity but also increases false positives; however, NIPT is very specific, [1] so most false-positive results obtained in the first stage are identified in the second stage. In addition, positive results from the first stage could be followed by reflexive NIPT. When tested this way, contingent NIPT would spare women the anxiety associated with false-positive results.[7] Because it is applied to a small subset of pregnancies, contingent NIPT has the potential to reduce costs relative to universal NIPT screening with little loss of accuracy. Thus, contingent NIPT may be a cost-effective alternative to universal NIPT and MSS.

The risk cutoff of the primary screen is a key design factor for contingent NIPT policies because it affects both screening performance (sensitivity and specificity) and downstream costs. Thus, it is important to determine the best cutoff point of the primary screen to optimize the overall cost-effectiveness of a contingent screening policy. We refer to such a screening process as an optimized contingent NIPT. To our knowledge, the optimal cutoff has not been determined.

Several studies have examined the cost effectiveness of contingent screening policies. There have been two approaches. Some studies used risk cutoffs similar to those used in MSS [8–11] where others compared a wide range of risk cutoffs. [5–7] Neither of these approaches uses an optimized cutoff. Studies to identify the optimal risk cutoff of the primary screen are needed to compare MSS and universal NIPT to the best available contingent NIPT policy.

The optimal cutoff for contingent screening balances screening costs (cases referred to second stage NIPT) and downstream costs (medical costs, productivity, indirect costs). Some downstream costs are only relevant in particular economic perspectives (societal, government,
Therefore, the optimal cutoff point of a contingent screening policy depends on the economic perspective. The evaluation of contingent NIPT relative to alternatives (MSS, universal NIPT) should be based on contingent NIPT policies that are optimized relative to a particular economic perspective.

This study compared the cost effectiveness of contingent NIPT to MSS and universal NIPT using three different economic perspectives: societal, governmental, and payer. For each perspective, we determined the optimal cutoff of the primary screen and then compared the performance of the optimized contingent NIPT policy to MSS and universal NIPT.

**Methods**

**Design**

We studied the cost effectiveness of routine use of contingent NIPT policies relative to conventional MSS and universal NIPT using a simulated population designed to represent the general population of women in the United States. We assumed that MSS and contingent NIPT used the combined serum test. We used a decision-analytic model because prenatal testing can be represented by a relatively simple sequence of decisions: Decision tree diagrams for screening protocols are provided in Figs 1–4. We based the cost effectiveness analysis upon a hypothetical cohort, and it is therefore exempt from institutional review board approval.

**Perspective and time horizon**

Our analysis included a societal perspective as recommended by many cost-effectiveness guidelines.[12,13] Although a societal perspective is recommended, decisions are often based on narrower perspectives and, for that reason, we also included government and payer perspectives. The societal perspective included immediate costs of screening and the direct and indirect lifetime costs. The government perspective included the immediate screening costs and direct lifetime medical and education costs. The payer perspective included only the immediate costs associated with screening.

**Standard of care and comparator**

We used MSS as a standard of care using the combined test (using pregnancy-associated plasma protein-A, free beta human chorionic gonadotropin and nuchal translucency ultrasound measurements). For this, we used a 2nd trimester risk cutoff of 1:270 for trisomy 21 and 1:100 for trisomy 18 and 13. We compared MSS to three alternatives: (1) universal NIPT, (2) contingent NIPT, and (3) no screening.

**Optimization of risk cutoff**

We determined the optimal cutoff by minimizing the expected total cost by simultaneously varying the decision thresholds for all three tests subject to the constraint that the detection rate had to be at least equivalent to conventional material screening. Because costs varied by perspective, optimal risk cutoffs were determined for each perspective. The optimization can be expressed as follows:

\[
TC_i = TC(L_{13,i}, L_{18,i}, L_{21,i}, C_i, p) = \min_{L_{13,i}, L_{18,i}, L_{21,i}} TC(L_{13,i}, L_{18,i}, L_{21,i}, C_i, p)
\]

\[
s.t. \quad DR_{cont}(L_{13,i}, L_{18,i}, L_{21,i}) > DR_{MSS}
\]

Where \(TC_i\) = expected total cost under economic perspective \(i\), \(L_{j,i}\) is the decision threshold for
marker \( j \) under perspective \( i \), \( C_i \) is the cost of an affected pregnancy under perspective \( i \), \( DR_{cont} \) is the first stage detection rate for contingent screening, \( DR_{MSS} \) is the detection rate of conventional MSS, and \( p \) is the vector of additional parameters that are invariant to the economic perspective (e.g., uptake rates, test accuracy, etc). The asterisks designate optimal values. Because conventional MSS is the current standard of care, we reasoned that a screening policy with lower accuracy would not be acceptable. We therefore constrained the optimization of contingent NIPT to meet or exceed the detection rate of current practice. We performed the optimization using a grid search. We generated a large grid of cost and threshold combinations. The optimization was performed in stages. Once we identified the neighborhood of the optimum, we created successively finer grids to identify the optimum risk thresholds. Grids were generating using @Risk (Palisade Corp, Ithaca, NY).

All results for contingent screens were based on optimized cutoffs. For simplicity, we will refer to an optimized contingent policy as a contingent NIPT policy.

Fig 1. Decision tree diagram for universal NIPT. We assumed that women with failed NIPT would be tested with serum screening and that women with a serum screen risk greater or equal to 1:270 would be offered diagnostic testing. The decision tree is continued in the diagnostic testing tree (Fig 4).
Screening performance

We used population parameters from the Serum Urine and Ultrasound Screening Study (SUR-USS) to estimate screening performance of maternal serum screening for trisomy 21[14,15] and used populations parameters from another study to estimate serum screening performance.

Fig 2. Decision tree diagram for contingent NIPT. We assumed that women with failed NIPT whose risk was higher than or equal to 1:270 on the initial serum screen would be offered diagnostic testing. The decision tree is continued in the diagnostic testing tree (Fig 4).

doi:10.1371/journal.pone.0131402.g002
for trisomy 18 and 13. Age-specific detection and false positive rates of serum screening was estimated by a Monte Carlo simulation performed using Stata 12.1. Multiples of median, standard deviations, correlation coefficients, and truncation limits provided by SUR-USS were used to create multivariate Gaussian distribution to simulate 1,000,000 marker sets of affected and unaffected pregnancies. Post-test risks were derived from the likelihood ratios and prior risk. For conventional maternal serum screening, a second trimester risk cut-off of 1:270 was used for trisomy 21 and a 1:100 risk cutoff was used for trisomy 18 and 13. Screen results were classified as “positive” if the post-test risk was equal to or greater than the specified risk cutoff and negative otherwise. Based on those results, age-specific detection and false-positive rates for the risk cutoffs were calculated. Detection rates of 99%, 96.8% and 92.1% were assumed for trisomy 21, 18, and 13 based on a meta-analysis of NIPT performance. An overall false positive rate of 0.41% for unaffected pregnancies was assumed based upon the individual reported false positive rates for trisomy 21, 18, and 13 reported in the same study. We assumed a 2.8% failure rate for NIPT due to low fetal fraction or assay failure based on a weighted average of studies using maternal blood drawn between 10–13 weeks of pregnancy.

Cost-effectiveness simulation

Our cost-effectiveness simulation was based on commonly used modeling practices, which incorporated a probabilistic sensitivity analysis and micro-simulation. The probabilistic
sensitivity analysis was conducted by repeating the micro-simulation 1,000 times. During each iteration of the probabilistic sensitivity analysis, the model costs and probabilities were randomly drawn and a micro-simulation was completed using the drawn values. Following standard practice, the costs were drawn from gamma distributions while the probabilities were drawn from beta distributions.[25] The definitions of beta and gamma distributions are provided in Table 1. The micro-simulations were conducted by simulating 1,000,000 pregnant women at 12 weeks of pregnancy. For each simulated woman, a maternal age was assigned based upon the maternal age distribution reported in the 2012 National Vital Statistics birth data.[26] The individual risk of an affected pregnancy, detection rate, and false-positive rate was determined by maternal age.

The effectiveness measure was the number of affected pregnancies detected. Simulation analyses were performed with TreeAge Pro 2012 software.[27]
Costs

We included the costs of screening, diagnosis, and termination of pregnancy as well as the lifetime costs associated with trisomy 21, 18, and 13. Lifetime costs represent the average difference in direct medical and educational costs between trisomy and an average individual in addition to the indirect costs of lost productivity due to morbidity and mortality associated with this syndrome.

We derived lifetime and termination costs from the literature.\(^{[28,29]}\) Lifetime costs for trisomy 21 were updated by using more recent survival data.\(^{[30,31]}\) We assumed that the annual costs of trisomies 13 and 18 were the same as the average annual costs of trisomy 21. We were not able to find survival data for trisomy 13 past the first year.\(^{[32,33]}\) We inflated lifetime costs and the cost of termination to reflect 2013 US dollars. We adjusted the medical portion of lifetime costs using the health care component of the personal consumption expenditure index.\(^{[34]}\) We adjusted the non-medical direct and indirect portions of lifetime costs using the employment cost index for civilian workers.\(^{[35]}\) As recommended, future costs incurred beyond one year were discounted to present value using

### Table 1. Model probabilities and costs.

| Probabilities                                           | Mean   | 95th% CI     | Parameters of beta distribution | Parameters of gamma distribution |
|---------------------------------------------------------|--------|--------------|---------------------------------|---------------------------------|
|                                                         |        |              | alpha                          | beta                            |
| MSS uptake, \(U_{MSS}\)                               | 69%    | 64%-74%      | 226.104                        | 101.583                         |
| Increase in contingent NIPT uptake over MSS, \(\Delta U_{cNIPT}\) | 8.2%   | 4.6%-12.6%   | 14.606                         | 163.516                         |
| Increase in universal NIPT uptake over MSS, \(\Delta U_{uNIPT}\)  | 13.5%  | 7.6%-20.8%   | 13.705                         | 87.814                          |
| Diagnostic testing uptake                               | 66%    | 61%-71%      | 226.923                        | 116.899                         |
| Procedure-related fetal loss                            | 0.22%  | 0%-1.16%     | 0.447                          | 202.595                         |
| Termination rate of trisomy 21                          | 80%    | 74%-86%      | 135.790                        | 33.948                          |
| Termination rate of trisomy 18                          | 80%    | 73%-87%      | 99.552                         | 24.888                          |
| Termination rate of trisomy 13                          | 92%    | 85%-97%      | 71.336                         | 6.203                           |
| NIPT detection rate of trisomy 21                        | 99%    | 98.3%-99.5%  | 1,044.886                      | 10.554                          |
| NIPT detection rate of trisomy 18                        | 96.8%  | 95%-98.2%    | 448.991                        | 14.843                          |
| NIPT detection rate of trisomy 13                        | 92.1%  | 86.9%-96.1%  | 120.738                        | 10.356                          |
| NIPT false positive rate                                 | 0.41%  | 0.29%-0.55%  | 36.775                         | 8,944.280                       |
| NIPT failure rate due to low fetal fraction             | 2.8%   | 1.2%-5.1%    | 7.291                          | 253.092                         |
| Costs                                                   |        |              |                                |                                 |
| Combined screen                                         | $166   | $95-$257     | 16                             | 10.375                          |
| Cost of NIPT                                            | $400   | $229-$619    | 16                             | 25                              |
| Cost of CVS                                             | $1,010 | $577-$1,562  | 16                             | 63.125                          |
| Cost of genetic counseling                               | $160   | $91-$247     | 16                             | 10                              |
| Termination of pregnancy                                | $581   | $332-$898    | 16                             | 36.313                          |
| Direct lifetime costs of trisomy 21                     | $427.577 | $244,397-$661,147 | 16 | 26,723.563 |
| Indirect lifetime costs of trisomy 21                   | $1,069,195 | $611,137-$1,563,257 | 16 | 66,824.688 |
| Direct lifetime costs of trisomies 13 and 18             | $37,971 | $21,704-$58,713 | 16 | 2,373.188 |
| Indirect lifetime costs of trisomies 13 and 18          | $1,363,877 | $779,574-$2,108,913 | 16 | 85,242.313 |

A standard deviation of 25% of the mean was assumed for the percentage increases for contingent NIPT and universal NIPT uptake. As standard practice, normal distributions of probabilities were approximated with beta distributions. Normal distributions of costs were approximated with gamma distributions.

doi:10.1371/journal.pone.0131402.t001

Costs

We included the costs of screening, diagnosis, and termination of pregnancy as well as the lifetime costs associated with trisomy 21, 18, and 13. Lifetime costs represent the average difference in direct medical and educational costs between trisomy and an average individual in addition to the indirect costs of lost productivity due to morbidity and mortality associated with this syndrome.

We derived lifetime and termination costs from the literature.\(^{[28,29]}\) Lifetime costs for trisomy 21 by Waitzman et al. were updated by using more recent survival data.\(^{[30,31]}\) We assumed that the annual costs of trisomies 13 and 18 were the same as the average annual costs of trisomy 21. We were not able to find survival data for trisomy 13 past the first year. We therefore assumed that the survival for trisomy 13 was the same as the survival for trisomy 18 past the first year.\(^{[32,33]}\) We inflated lifetime costs and the cost of termination to reflect 2013 US dollars. We adjusted the medical portion of lifetime costs using the health care component of the personal consumption expenditure index.\(^{[34]}\) We adjusted the non-medical direct and indirect portions of lifetime costs using the employment cost index for civilian workers.\(^{[35]}\) As recommended, future costs incurred beyond one year were discounted to present value using
an annual rate of 3%. Additional explanation of the lifetime cost estimates is provided in S1 Text.

The costs of serum screenings, diagnostic testing, and genetic counseling were derived from the 2013 Medicare Physician Fee Schedule (MPFS), which is often used to approximate the resource value of medical care. These costs included procedure costs as well as genetic counseling.

The cost of NIPT testing is uncertain. The list price can serve as an indicator of cost, but list prices show wide variation. Because NIPT providers utilize similar techniques, we would expect the underlying costs to be similar for all test providers. Therefore, the variation in price is more likely an indication of variation in profit margins rather than variation in costs. For genetic testing, these margins can be as high as 90%. For that reason, we based the resource cost of NIPT on the lowest priced test (NIFTY offered by Beijing Genomics Institute in the UK for approximately $500). We assumed a conservative profit margin of 20% for a unit cost of $400. This cost is consistent with cost estimates published in previous cost-effectiveness studies.

We assumed costs had a standard deviation that was 25 percent of the mean. Gamma cost distributions were estimated using the mean and standard deviation values. The costs are summarized in Table 1.

Baseline model

Baseline model inputs are shown in Table 1. The baseline uptake rate for conventional screening was assumed to be 69%. For contingent and universal NIPT, we assumed screening uptake increased by 8.2% and 13.5% relative to MSS, based upon a recent study of potential uptake of NIPT. Therefore, we modeled contingent and universal NIPT uptake as follows:

\[ U_{cNIPT} = U_{cMSS} \times (1 + \Delta U_{cNIPT}) \]  
\[ U_{uNIPT} = U_{cMSS} \times (1 + \Delta U_{uNIPT}) \] 

Where \( U_{cMSS} \) is the baseline uptake based on conventional MSS, \( U_{cNIPT} \) and \( U_{uNIPT} \) are the uptake for contingent NIPT and universal NIPT. \( \Delta U_{cNIPT} \) and \( \Delta U_{uNIPT} \) are the fractional change in uptake relative to \( U_{cMSS} \). We assume that \( \Delta U_{cNIPT} \) and \( \Delta U_{uNIPT} \) are 0.082 and 0.135. This resulted in a baseline uptake of approximately 75% for contingent NIPT and 78% for universal NIPT.

For contingent screening, we assumed that all primary screens exceeding the risk threshold (i.e., “positive” on the primary screen) were followed by reflexive NIPT. A contingent NIPT screen was classified as positive only if the primary and secondary screens were both positive. We assumed that all positive screen results (MSS, contingent NIPT, universal NIPT) were followed by diagnostic testing at an acceptance rate of 66%. We assumed that the termination rates for pregnancies diagnosed as positive were 80% for trisomy 21, 80% for trisomy 18, and 92% for trisomy 13. We assumed spontaneous fetal loss rates 43%, 72%, and 49% for trisomy 21, 18, and 13 respectively. Procedure-related fetal loss from chorionic villus sampling (CVS) was assumed to be 0.22% based on a recently published meta-analysis.

We assumed that the technical failure rate of NIPT was 2.8%. To our knowledge, there is no standard protocol for NIPT failure. For simplicity, we assumed NIPT would not be repeated in the event of an NIPT test failure. In this event, we assumed that women who elected contingent NIPT would be referred to invasive diagnostic testing based on MSS results, For those who elected universal NIPT, failures would be referred for MSS, and those who were...
classified as high risk (i.e., those with a trisomy 21 risk equal to or greater than 1:270 or a trisomy 13 or 18 risk equal to or greater than 1:100) would be referred for invasive diagnostic testing.

Sensitivity analysis

Sensitivity analysis was performed using one-way and probabilistic sensitivity analysis. One-way sensitivity analyses were conducted to determine the individual impact of each input parameter value on cost-effectiveness ratios. Probabilistic sensitivity analysis was conducted to determine the overall uncertainty in the cost effectiveness due to the combined impact of uncertainty in the underlying model inputs. The parameters of the distributions are reported in Table 1. The objectives and, therefore, the parameters, of a one-way sensitivity analysis differ from the objectives of a probabilistic sensitivity analysis. For example, a one-way analysis may be designed to determine the point at which the best strategy changes (which are not necessarily plausible), whereas a probabilistic sensitivity should investigate the sensitivity over plausible ranges of the input variables.

Terminology. A screening policy is said to be strictly dominated by another policy if it is both more costly and more expensive.[12] A policy is dominated by extension if a combination of alternatives is less costly.[12] For example, policy A is dominated by extension by policies B and C if, on average, a combination of policies B and C (X% policy B, 1-X% policy C) is less expensive and more effective than policy A.

Because there is no agreed-upon willingness-to-pay threshold for trisomy screening, we deemed NIPT strategies as cost effective if they dominated MSS (the current standard of care) strictly or by extension.

Results

The prevalence at 12 weeks was approximately 1 in 301 for trisomy 21, 1 in 1,170 for trisomy 18, and 1 in 3,627 for trisomy 13. In the absence of screening, this resulted in a lower birth prevalence of 1 in 528, 1 in 4,174, and 1 in 7,084 live births for trisomy 21, 18, and 13 respectively due to spontaneous fetal loss. These rates are consistent with reported birth prevalence for these trisomies.[19] The optimal risk cutoffs, percentage of women screened receiving NIPT, detection rates, false positive rates, and number of failed NIPTs are provided in Tables 2 and 3. Total costs, cases detected, and incremental cost effectiveness ratios (ICERs) are provided in Table 4.

Societal perspective

Both direct and indirect lifetime costs were included in the analysis from a societal perspective. The optimized contingent NIPT screening policy had detection rates of 93.6%, 92.7%, and 77.7%, for trisomy 21, 18, and 13 respectively. In contrast, the detection rates were 84.4%, 75.8%, and 62.8% for conventional MSS and 98.7%, 96.4%, and 91.5% for universal NIPT.

| Perspective   | Trisomy 21 | Trisomy 18 | Trisomy 13 | NIPT referral rate |
|---------------|------------|------------|------------|--------------------|
| Societal      | 1:1515     | 1:1905     | 1:860      | 24.0%              |
| Government    | 1:420      | 1:145      | 1:175      | 8.7%               |
| Payer         | 1:315      | 1:115      | 1:175      | 7.0%               |

doi:10.1371/journal.pone.0131402.t002

classified as high risk (i.e., those with a trisomy 21 risk equal to or greater than 1:270 or a trisomy 13 or 18 risk equal to or greater than 1:100) would be referred for invasive diagnostic testing.

Sensitivity analysis

Sensitivity analysis was performed using one-way and probabilistic sensitivity analysis. One-way sensitivity analyses were conducted to determine the individual impact of each input parameter value on cost-effectiveness ratios. Probabilistic sensitivity analysis was conducted to determine the overall uncertainty in the cost effectiveness due to the combined impact of uncertainty in the underlying model inputs. The parameters of the distributions are reported in Table 1. The objectives and, therefore, the parameters, of a one-way sensitivity analysis differ from the objectives of a probabilistic sensitivity analysis. For example, a one-way analysis may be designed to determine the point at which the best strategy changes (which are not necessarily plausible), whereas a probabilistic sensitivity should investigate the sensitivity over plausible ranges of the input variables.

Terminology. A screening policy is said to be strictly dominated by another policy if it is both more costly and more expensive.[12] A policy is dominated by extension if a combination of alternatives is less costly.[12] For example, policy A is dominated by extension by policies B and C if, on average, a combination of policies B and C (X% policy B, 1-X% policy C) is less expensive and more effective than policy A.

Because there is no agreed-upon willingness-to-pay threshold for trisomy screening, we deemed NIPT strategies as cost effective if they dominated MSS (the current standard of care) strictly or by extension.

Results

The prevalence at 12 weeks was approximately 1 in 301 for trisomy 21, 1 in 1,170 for trisomy 18, and 1 in 3,627 for trisomy 13. In the absence of screening, this resulted in a lower birth prevalence of 1 in 528, 1 in 4,174, and 1 in 7,084 live births for trisomy 21, 18, and 13 respectively due to spontaneous fetal loss. These rates are consistent with reported birth prevalence for these trisomies.[19] The optimal risk cutoffs, percentage of women screened receiving NIPT, detection rates, false positive rates, and number of failed NIPTs are provided in Tables 2 and 3. Total costs, cases detected, and incremental cost effectiveness ratios (ICERs) are provided in Table 4.

Societal perspective

Both direct and indirect lifetime costs were included in the analysis from a societal perspective. The optimized contingent NIPT screening policy had detection rates of 93.6%, 92.7%, and 77.7%, for trisomy 21, 18, and 13 respectively. In contrast, the detection rates were 84.4%, 75.8%, and 62.8% for conventional MSS and 98.7%, 96.4%, and 91.5% for universal NIPT.
women screened with contingent NIPT, approximately 24% were classified as “high risk” in the primary screen and referred for NIPT. Contingent NIPT had a false positive rate of 0.09%, conventional MSS had a false positive rate of 5.6%, and universal NIPT had a false positive rate of 0.9%. Contingent NIPT also had fewer test failures than universal NIPT. Only 0.66% of those screened with contingent NIPT had a technical failure whereas 2.8% of women screened with universal NIPT failed to obtain a result.

No screening, MSS, and contingent NIPT were all dominated by universal NIPT. Out of 1,000,000 pregnancies, replacing MSS with universal NIPT would result in an increase of 893 detections and a cost savings of approximately $170 million (Table 4).

We conducted one-way sensitivity analysis of the ICERs (Fig 5). Universal NIPT remained less costly than conventional MSS so long as the cost of NIPT was below $619. In the probabilistic sensitivity analysis, universal NIPT was more effective 100% of the time and less costly 91.1% of the time compared to MSS (Fig 6).

### Government perspective

Indirect costs were not included in the government perspective. When indirect lifetime costs were excluded from the analysis, the contingent NIPT policy had detection rates of 87%, 82.1%, and 77.7%, for trisomy 21, 18, and 13, a false positive rate of 0.033%, and a failure rate

| Table 3. Detection rates, false positive rates, optimal risk cutoffs, and NIPT failure rates. |
|-----------------------------------------------|-----------------|-----------------|-----------------|
|                                      | Detection rates | False positive rates | NIPT failure rates |
|                                      | Trisomy 21      | Trisomy 18      | Trisomy 13      |  |
| Universal NIPT                        | 99%            | 96.8%           | 92.1%           | 0.4%         | 2.8%          |
| MSS                                    | 84.8%          | 75.8%           | 62.8%           | 5.6%         | 0%            |
| Contingent NIPT                       |                |                 |                 |              |              |
| Societal perspective                  | 93.6%          | 92.7%           | 77.7%           | 0.094%       | 0.66%         |
| Government perspective                | 87%            | 82.1%           | 63.3%           | 0.033%       | 0.24%         |
| Payer perspective                     | 85.1%          | 75.6%           | 63.3%           | 0.026%       | 0.19%         |

do:10.1371/journal.pone.0131402.t003

| Table 4. Total cost, cases detected, incremental costs, incremental cases detected and incremental cost effectiveness ratio (ICER). |
|-------------------------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                                   | Total cost      | Cases detected | Incremental costs | Incremental cases detected | ICER          |
| Societal perspective                              |                 |                |                  |                             |              |
| No screening                                     | $3,347,297,152  | 0              |                  |                             | Strictly dominated |
| MSS                                              | $2,475,580,143  | 2,516           |                  |                             | Strictly dominated |
| Contingent NIPT                                  | $2,315,959,639  | 3,077           |                  |                             | Strictly dominated |
| Universal NIPT                                   | $2,305,749,493  | 3,409           |                  |                             |                |
| Government perspective                           |                 |                |                  |                             |              |
| No screening                                     | $822,000,565    | 0              |                  |                             | Strictly dominated |
| MSS                                              | $711,465,188    | 2,516           |                  |                             | Strictly dominated |
| Contingent NIPT                                  | $693,996,197    | 2,817           |                  |                             |                |
| Universal NIPT                                   | $814,224,159    | 3,409           | $120,277,962     | 592                        | $203,088       |
| Payer perspective                                |                 |                |                  |                             |              |
| No screening                                     | $0              | 0              |                  |                             |                |
| MSS                                              | $142,723,273    | 2,516           |                  |                             | Dominated by extension |
| Contingent NIPT                                  | $148,208,927    | 2,729           | $148,208,927     | 213                        | $25,754        |
| Universal NIPT                                   | $327,675,783    | 3,409           | $179,466,856     | 680                        | $263,922       |

do:10.1371/journal.pone.0131402.t004
of 0.24%. Approximately 8.7% of women screened by contingent NIPT received NIPT after the initial screen.

Contingent NIPT dominated MSS when evaluated from the government perspective. Out of 1,000,000 pregnancies, replacing combined MSS with contingent NIPT would result in an increase of 301 detections and a cost savings of approximately $17.5 million (Table 4). Universal NIPT was more effective but also more costly than contingent NIPT. Universal NIPT would increase the number of cases detected by contingent NIPT by 592 and increase costs by $120 million, for an ICER of $203,088 per additional case detected. The one-way analysis shows that contingent NIPT screening dominated MSS unless the cost of NIPT exceeded $663 (Fig 7). In the probabilistic sensitivity analysis, contingent screening was more effective 100% of the time and less costly 87% of the time compared to MSS (Fig 8).

Payer perspective
When all lifetime costs were excluded from the analysis, the optimal risk cutoffs resulted in detection rates of 85.1%, 75.8%, and 63.3%, for trisomy 21, 18, and 13, respectively, a false
positive rate of 0.026%, and a failure rate of 0.19%. Approximately 7% of women screened with the contingent NIPT received NIPT after the initial screen.

No screening is the least costly strategy, followed by MSS, contingent NIPT, and universal NIPT. Although contingent NIPT is more effective and more costly than MSS in terms of cost per additional detection, contingent NIPT is a more efficient strategy (Table 4). Compared to no screening, MSS would cost $56,726 per case detected; however, contingent NIPT would cost $54,309 for each detection. Therefore, contingent NIPT dominates MSS by extension.

Compared to contingent NIPT, universal NIPT would increase the number of cases detected by 680 and increase costs by $179 million, for an ICER of $263,922 per additional case detected. The one-way analysis shows contingent NIPT was less costly than MSS when (1) the cost of NIPT was below $293, (2) contingent NIPT uptake was below 72%, and (3) the cost of invasive screening was above $1,235 (Fig 9). In the probabilistic sensitivity analysis, contingent

Fig 7. One-way sensitivity analysis of contingent NIPT vs MSS from a government perspective. Below are the one-way sensitivity analysis results of ICER between contingent NIPT and MSS. Contingent NIPT is less costly than MSS as long as the cost of NIPT remains below $663.

doi:10.1371/journal.pone.0131402.g007

Fig 8. Scatter plot of probabilistic sensitivity analysis of contingent NIPT vs. MSS from a government perspective. The figure below plots the incremental cost and effectiveness results from 1,000 simulations. Compared to MSS, there is a 100% probability that contingent NIPT is more effective and a 87% probability that contingent NIPT is less costly.

doi:10.1371/journal.pone.0131402.g008
screening was more effective 100% of the time and more costly 73.2% of the time compared to MSS (Fig 10).

Discussion

We compared the cost effectiveness of four screening policies to identify fetal trisomies: (1) no screening, (2) conventional MSS, (3) universal NIPT screening, and (4) optimized contingent NIPT. We conducted our analysis from three different perspectives: societal, government, and payer.

We optimized the risk cutoff used to classify “high-risk” pregnancies in the primary stage of the contingent NIPT screen. We found that the optimal risk cutoff depended on the cost perspective. The optimal risk cutoff of the primary stage decreased when more downstream costs were included in the analysis. Lower risk cutoffs in the first stage increased the referral rate to
the second stage (NIPT) which, in turn, increased the detection rate. The risk cutoffs were lowest when optimized for the societal perspective and highest when optimized for the payer perspective.

We found that the best screening policy depended on the economic perspective. When analyzed from a societal perspective, universal NIPT was both more effective and less costly than contingent NIPT. Universal NIPT was also less costly than MSS. Replacing MSS with universal NIPT would result in a 35.5% increase in total cases detected and 6.9% reduction in total costs.

From a government perspective, contingent NIPT dominated MSS and was the least costly strategy. Under this perspective, the optimized risk cutoffs would result in a 12% increase in the number of total cases detected and a 2.5% reduction in costs. In contrast to a societal perspective, the government perspective excluded the indirect costs from the analysis. When indirect costs are no longer included, universal NIPT is not a cost-effective alternative to MSS unless there is a substantial willingness to pay for the test. For universal NIPT to be a cost-effective replacement for MSS, there must be a willingness to pay of $203,088 per detection.

From a payer perspective, MSS is the least costly screening strategy. Although MSS was less costly, contingent NIPT dominated MSS by extension. The ICER between no screening and contingent NIPT was $54,309 per case detected; however, a comparison of no screening and MSS produces an ICER of $56,726 per case detected. Given that MSS is currently the standard of care, we can reasonably assume that there is at least a willingness to pay of $56,726 per case detected, making a contingent NIPT a cost-effective alternative to MSS from a payer perspective.

Contingent and universal NIPT produced fewer false positive results than MSS. MSS had a false positive rate of 5.6%, universal NIPT had a false positive rate of 0.4%, and all contingent NIPT polices had false positive rates below 0.1%. Thus, contingent NIPT can obtain higher detection rates than MSS with a relatively small increase (0.3%) in the overall false positive rate.

The first stage of contingent NIPT produces a higher level of false positive results than conventional MSS. Unlike conventional MSS, most false positives from the first stage of contingent screening are identified in the second stage so that the overall false positive rate is lower than MSS and only slightly lower than universal NIPT. The high false positive rate of first stage could be a problem if women were provided these results; however, we believe that contingent NIPT should be implemented as a testing system that produces a single test result. Positive results from the first stage would be reflexed to NIPT. Women would only be given the final result and would not be informed of the preliminary false positive result. This approach would spare women the anxiety associated with false positive results.

Previous studies have examined the cost effectiveness of changing the risk cutoff in the primary screen; however, none of these studies included the downstream costs of trisomy births that result from false negative results.[5–7] By including both the immediate costs of screening and the downstream costs of false negative results, we were able to optimize the decision limit. Therefore, our findings provide a new approach to setting the risk thresholds for contingent NIPT.

Our results are consistent with the results of three previous studies that found contingent NIPT to be a cost-effective alternative to conventional MSS.[5,8,9] However, our analysis used multiple perspectives and found risk cutoffs for each perspective that minimized the overall costs of contingent NIPT.

We are unaware of a standard protocol for failed NIPT. We assumed that pregnancies would be classified by conventional MSS in the event of NIPT failure. For contingent NIPT, we assumed that women with a risk greater than or equal to 1:270 on the initial serum screen would be offered invasive testing. Similarly, for universal NIPT we assumed that cases with
NIPT failure would be tested with MSS and those with risks greater or equal to 1:270 would be offered invasive testing. When NIPT fails, approximately 56%-83% are successful after another blood draw.[24,65–67] Because some cases are probably redrawn, our analysis probably underestimated the overall detection rate of contingent and universal NIPT. We conducted sensitivity analyses to examine the impact of our assumptions regarding NIPT failure. We found that our results were insensitive to the assumptions. Contingent NIPT was particularly insensitive to this change because only a subset of women initially screened received follow-up NIPT.

The unit cost of NIPT is uncertain. Prices for NIPT testing range from $500 to $2100; however, prices do not necessarily reflect costs. The relevant cost in a cost-effectiveness analysis is the resource cost, or the cost to perform the test. Although prices cannot be used directly, we used prices to estimate underlying costs. We reasoned that the producer with the lowest price is most likely making a profit and the variability in price most likely represents variation in profit margins rather than variation in costs. Thus, the lowest price most likely represents an upper bound on the cost. Further, if the variation in prices reflects variation in costs, the lowest cost producer will eventually dominate and is the most relevant cost for the analysis. For that reason, we used the lowest list price ($500) to estimate the cost of NIPT. We assumed a 20% profit margin and used a unit cost of $400 per test. This cost estimate is consistent with previous published results.[4,38] Our sensitivity analysis demonstrated that even at a cost of $800, contingent NIPT was less costly and more effective than conventional screening.

Our analysis assumed that CVS, rather than amniocentesis was used for diagnostic testing. Our model simulates screening at the 12th week. Amniocentesis is usually not performed until the 15th week. We assumed that most women would prefer rapid resolution of a positive screen result and, for that reason, would prefer CVS in the 12th week over amniocentesis at week 15. However, our results are insensitive to this assumption. The number of trisomy cases detected would remain the same while the total costs would be slightly lower due to the small difference in cost between CVS and amniocentesis. Therefore, our conclusions would remain unchanged even if we assumed that diagnostic testing were conducted with amniocentesis.

We conducted extensive sensitivity analysis and probabilistic sensitivity analysis. Our results were most sensitive to changes in the lifetime costs, the increase in uptake of NIPT policies relative to MSS uptake (i.e., ΔU_{NIPT} and ΔU_{MSS}), uptake of MSS (U_{MSS}), and the cost of NIPT. Because of the uncertainty regarding the lifetime cost estimates of trisomies 13 and 18, we varied these costs over a wide range in the one-way sensitivity analysis. We found that our results were insensitive to assumptions concerning the lifetime costs associated with trisomies 13 and 18.

Our study had the following limitations regarding the reliability of the lifetime cost estimates. First, the data used to estimate lifetime costs in our analysis is roughly two decades old.[29] Although we adjusted the initial estimates by accounting for inflation and changes in life expectancy, these adjustments do not take into consideration changes in treatment. For example, advances in care may increase the intensity of treatment, therefore increasing lifetime medical expenses.[68] Second, in the absence of lifetime cost estimates for trisomies 13 and 18, we made several simplifying assumptions in order to estimate these costs. Cost data on trisomies 13 and 18 are difficult to obtain. Therefore, we used the annual costs of Down syndrome provided by Waitzman et al. Although trisomies 13 and 18 have similar one-year survival rates, [32,69–71] we were unable to find survival estimates beyond one year for trisomy 13; therefore, we assumed that survival rates for trisomy 13 were the same as for trisomy 18 beyond year one.

Because of the uncertainty of the lifetime estimates, we conducted extensive sensitivity analysis on these costs (see Figs 5, 7, and 9). Our conclusions held even when lifetime costs were reduced by 50%, with the following exception. From a societal perspective, universal NIPT no longer dominated contingent NIPT once the lifetime costs of trisomy 21 were below $1.3
million or when the lifetime costs of trisomies 13 and 18 were below $704,000. However, contingent NIPT remained less costly than MSS over the full range of lifetime costs that was covered in the one-way analysis. This remained true even when the lifetime cost of trisomies 13 and 18 were excluded from the analysis, due to the low birth prevalence of these trisomies. Therefore, our conclusions are robust even when taking into account uncertainty surrounding the lifetime cost estimates, particularly those of trisomies 13 and 18.

For this reason, assumptions about trisomies 13 and 18 have relatively little impact on the analysis.

Our study also has several strengths. Our analysis included trisomies 13 and 18, which have only been included in one previous analysis. Although other studies have investigated contingent policies, we identified the optimal risk cutoffs and were able to compare the cost effectiveness of an optimal contingent policy against the cost effectiveness of universal NIPT and MSS. Our analysis shows the potential cost savings of contingent NIPT. We included multiple cost perspectives. We analyzed cost effectiveness from a broad allocative standpoint (societal perspective), as well as from narrower perspectives that would be relevant to government and payer decision makers. Finally, our results were robust. We found that contingent NIPT was less costly than MSS over a wide range of costs and probabilities used in our analysis.

Conclusion

From a societal perspective, universal NIPT is a cost-effective alternative to MSS and contingent NIPT. When viewed from government or payer perspectives, contingent NIPT is cost-effective relative to MSS but is both less costly and less effective than universal NIPT. In these cases, the choice of policy depends on the willingness to pay for additional detections. Adopting universal NIPT would cost $203,088 for each additional case detected from a government perspective and $263,922 for each additional case detected from a payer perspective.

Supporting Information

S1 Text. Explanation of Lifetime Cost Estimates.
(DOCX)

Acknowledgments

We would like to thank Dr. Norman J. Waitzman, Professor of Economics, University of Utah, for his advice and assistance regarding the adjustment of the lifetime cost estimates.

Author Contributions

Conceived and designed the experiments: BSW RLS. Performed the experiments: BSW RLS. Analyzed the data: RLS BSW ERA BRJ DGG REN. Wrote the paper: BSW RLS REN ERA BRJ DGG.

References

1. Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH (2014) Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther 35: 156–173. PMID: 24513694
2. Non-Invasive Prenatal Testing (NIPT). this is my: Health Screening & Ultrasound Centres.
3. Agarwal A, Sayres LC, Cho MK, Cook-Deegan R, Chandrasekharan S (2013) Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn 33: 521–531. doi: 10.1002/pd.4101 PMID: 23686656
4. Walker BS, Jackson BR, LaGrave D, Ashwood ER, Schmidt RL (2014) A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome. Prenat Diagn.

5. Cuckle H, Benn P, Pergament E (2013) Maternal cfDNA screening for Down syndrome—a cost sensitivity analysis. Prenat Diagn 33: 636–642. doi: 10.1002/pd.4157 PMID: 23674341

6. Morris S, Karlsen S, Chung N, Hill M, Chitty LS (2014) Model-based analysis of costs and outcomes of non-invasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One 9: e93559. doi: 10.1371/journal.pone.0093559 PMID: 24714162

7. Wald NJ, Bestwick JP (2013) Incorporating DNA sequencing into current prenatal screening practice for Down's syndrome. PLoS One 8: e58732. doi: 10.1371/journal.pone.0058732 PMID: 23527014

8. Garfield SS, Armstrong SO (2012) Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. Journal of Managed Care Medicine 15: 32–39.

9. Song K, Musci TJ, Caughey AB (2013) Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med 26: 1180–1185. doi: 10.3109/14767058.2013.770464 PMID: 23356557

10. O’Leary P, Maxwell S, Murch A, Hendrie D (2013) Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. Aust N Z J Obstet Gynaecol 53: 425–433. doi: 10.1111/ajo.12136 PMID: 24090461

11. Beulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, et al. (2014) The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur J Obstet Gynecol Reprod Biol 182: 53–61. doi: 10.1016/j.ejogrb.2014.08.028 PMID: 25238658

12. Drummond M, Sculpher M, Torrance G, O'Brien B, Stoddart G (2005) Methods for the Economic Evaluation of Health Care Programmes: Oxford University Press, Incorporated.

13. Gold M, Siegel J, Russell L, Weinstein M (1996) Cost-Effectiveness in Health and Medicine. USA: Oxford University Press.

14. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, et al. (2003) First and second trimester antenatal screening for Down's syndrome: The results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 10: 56–104. PMID: 14746340

15. Wald N, Rodeck C, Rudnicka A, Hackshaw A (2004) Nuchal translucency and gestational age. Prenatal Diagnosis 24: 150–151. PMID: 14974125

16. Bestwick JP, Huttly WJ, Wald NJ (2013) Detection of trisomy 18 and trisomy 13 using first and second trimester Down's syndrome screening markers. J Med Screen 20: 57–65. doi: 10.1177/0969141313484904 PMID: 23761419

17. (2011) Stata Statistical Software: Release 12. College Station, TX, USA: StataCorp.

18. Wald N, Leck I (2000) Antenatal and Neonatal Screening USA: Oxford University Press.

19. Savva GM, Walker K, Morris JK (2010) The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21 (Down syndrome). Prenat Diagn 30: 57–64. doi: 10.1002/pd.2403 PMID: 19911411

20. Morris JK, Mutton DE, Alberman E (2002) Revised estimates of the maternal age specific live birth prevalence of Down's syndrome. J Med Screen 9: 2–6. PMID: 11943789

21. Chiu RW, Akolekar R, Zheng YW, Leung TY, Sun H, et al. (2011) Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 342: c7401. doi: 10.1136/bmj.c7401 PMID: 21224326

22. Ashoor G, Syngelaki A, Wagner M, Birdir C, Nicolaides KH (2012) Chromosome-selective sequencing of maternal plasma cell-free DNA for first-trimester detection of trisomy 21 and trisomy 18. Am J Obstet Gynecol 206: 322.e321-325. doi: 10.1016/j.ajog.2012.01.029 PMID: 22464073

23. Nicolaides KH, Syngelaki A, Ashoor G, Birdir C, Touzet G (2012) Non-invasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 207: 374.e371-376. doi: 10.1016/j.ajog.2012.08.033 PMID: 23107079

24. Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH (2013) Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies. Ultrasound in Obstetrics and Gynecology 42: 34–40. doi: 10.1002/uog.12504 PMID: 23744609

25. Briggs AH, Claxton K, Sculpher MJ (2006) Decision Modelling for Health Economic Evaluation: Oxford University Press.

26. (2012) Centers for Disease Control and Prevention. National Center for Health Statistics. VitalStats.

27. (2012) TreeAge Pro 2012. TreeAge Software Inc.

28. Jones RK, Kooistra K (2011) Abortion incidence and access to services in the United States, 2008. Perspectives Reprod Health 43: 41–50. doi: 10.1363/4304111 PMID: 21388504
29. Waitzman NJ, Scheffler RM, Romano PS (1996) The cost of birth defects: estimates of the value of prevention: University Press of America.

30. Kucik JE, Shin M, Siffl C, Marengo L, Correa A (2013) Trends in survival among children with Down syndrome in 10 regions of the United States. Pediatrics 131: e27–36. doi: 10.1542/peds.2012-1616 PMID: 23248222

31. Day SM, Strauss DJ, Shavelle RM, Reynolds RJ (2005) Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 47: 171–176. PMID: 15739721

32. Vendola C, Canfield M, Daiger SP, Gambello M, Hashmi SS, et al. (2010) Survival of Texas infants born with trisomies 21, 18, and 13. Am J Med Genet A 152a: 360–366. doi: 10.1002/ajmg.a.33156 PMID: 20082470

33. Niedrist D, Riegel M, Achermann J, Schinzel A (2006) Survival with trisomy 18—data from Switzerland. Am J Med Genet A 140: 952–959. PMID: 16528741

34. Personal Consumption Expenditures Index. Bureau of Economic Analysis.

35. Employment Cost Index. Bureau of Labor Statistics.

36. CMS.gov Centers for Medicare & Medicaid Services.

37. Langreth R, Pettypiece S (June 14, 2013) Myriad Gene Patent Ruling Triggers Race for Cancer Tests. Bloomberg.

38. Ohno M, Caughey A (2013) The role of noninvasive prenatal testing as a diagnostic versus a screening tool—a cost-effectiveness analysis. Prenatal Diagnosis 33: 630–635. doi: 10.1002/pd.4156 PMID: 23674316

39. Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE (2013) Screening for down syndrome in the United States: results of surveys in 2011 and 2012. Arch Pathol Lab Med 137: 921–926. doi: 10.5858/arpam.2012-0319-CP PMID: 23808464

40. Lewis C, Hill M, Silcock C, Daley R, Chitty LS (2014) Non-invasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. Bjog 121: 582–594. doi: 10.1111/1471-0528.12579 PMID: 24433394

41. Platt LD, Greene N, Johnson A, Zachary J, Thom E, et al. (2004) Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 104: 661–666. PMID: 15458882

42. Cunningham GC, Tompkinson DG (1999) Cost and effectiveness of the California triple marker prenatal screening program. Genet Med 1: 199–206. PMID: 11256673

43. Priest JH, FitzGerald JM, Haag MM, Streets K, Vanisko M, et al. (1998) Acceptance of amniocentesis by women in the state of Montana (USA) who are screen positive for Down's syndrome. J Med Screen 5: 178–182. PMID: 9934647

44. de la Vega A, Verdiales M, Leavitt G (2002) Method of risk assessment affects acceptance rate of amniocentesis. P R Health Sci J 21: 233–235. PMID: 12243114

45. Baker D, Teklehaymanot S, Hassan R, Guze C (2004) A look at a Hispanic and African American population in an urban prenatal diagnostic center: referral reasons, amniocentesis acceptance, and abnormalities detected. Genet Med 6: 211–218. PMID: 15266209

46. Currier R, Wu N, Van Meter K, Goldman S, Lorey F, et al. (2012) Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow-up services. Prenat Diagn 32: 1077–1083. doi: 10.1002/pd.3961 PMID: 22903386

47. Kazerouni NN, Currier B, Malm L, Riggle S, Hodgkinson C, et al. (2009) Triple-marker prenatal screening program for chromosomal defects. Obstet Gynecol 114: 50–58. doi: 10.1097/01.AOG. 0b013e3181a9479e PMID: 19546758

48. Won RH, Currier RJ, Lorey F, Towner DR (2005) The timing of demise in fetuses with trisomy 21 and trisomy 18. Prenat Diagn 25: 608–611. PMID: 16032775

49. Bishop J, Huether CA, Torfs C, Lorey F, Deddens J (1997) Epidemiologic study of Down syndrome in a racially diverse California population, 1989–1991. Am J Epidemiol 145: 134–147. PMID: 9006310

50. Forrester MB, Merz RD (2002) Pregnancy outcome distribution and prenatal diagnosis of autosomal abnormalities, Hawaii, 1986–1999. Teratology 66 Suppl 1: S7–11. PMID: 12239737

51. Knight GJ, Palomaki GE, Neveux LM, Smith DE, Kloza EM, et al. (2005) Integrated serum screening for Down syndrome in primary obstetric practice. Prenat Diagn 25: 1162–1167. PMID: 16231402

52. Shaffer BL, Caughey AB, Norton ME (2006) Variation in the decision to terminate pregnancy in the setting of fetal aneuploidy. Prenat Diagn 26: 667–671. PMID: 16724363

53. Benn PA (1998) Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies. Prenat Diagn 18: 319–324. PMID: 9602476
54. Wray AM, Landy HJ, Meck JM (2007) Patient decisions regarding prenatal aneuploid fluorescence in situ hybridization results. Int J Gynaecol Obstet 96: 103–107. PMID: 17239384
55. Caruso TM, Westgate MN, Holmes LB (1998) Impact of prenatal screening on the birth status of fetuses with Down syndrome at an urban hospital, 1972–1994. Genet Med 1: 22–28. PMID: 11261425
56. Kramer RL, Jarve RK, Yaron Y, Johnson MP, Lampinen J, et al. (1998) Determinants of parental decisions after the prenatal diagnosis of Down syndrome. Am J Med Genet 79: 172–174. PMID: 9788556
57. Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST (2006) Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 194: 127–130. PMID: 16389021
58. Perry S, Woodall AL, Pressman EK (2007) Association of ultrasound findings with decision to continue Down syndrome pregnancies. Community Genet 10: 227–230. PMID: 17895628
59. Horger EO 3rd, Finch H, Vincent VA (2001) A single physician’s experience with four thousand six hundred genetic amniocenteses. Am J Obstet Gynecol 185: 279–288. PMID: 11518880
60. Forrester MB, Merz RD (1999) Trisomies 13 and 18: prenatal diagnosis and epidemiologic studies in Hawaii, 1986–1997. Genet Test 3: 335–340. PMID: 10627940
61. Forrester MB, Merz RD (1999) Prenatal diagnosis and elective termination of Down syndrome in a racially mixed population in Hawaii, 1987–1996. Prenat Diagn 19: 136–141. PMID: 10215071
62. Morris JK, Wald NJ, Watt HC (1999) Fetal loss in Down syndrome pregnancies. Prenat Diagn 19: 142–145. PMID: 10215072
63. Morris JK, Savva GM (2008) The risk of fetal loss following a prenatal diagnosis of trisomy 13 or trisomy 18. Am J Med Genet A 146a: 827–832. doi: 10.1002/ajmg.a.32220 PMID: 18361449
64. Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F (2015) Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 45: 16–26. doi: 10.1002/uog.14636 PMID: 25042845
65. Wang E, Batey A, Struble C, Musci T, Song K, et al. (2013) Gestational age and maternal weight effects on fetal cell-free DNA in maternal plasma. Prenatal Diagnosis 33: 662–666. doi: 10.1002/pd.4119 PMID: 23553731
66. Hui L, Teoh M, da Silva Costa F, Ramsay P, Palma-Dias R, et al. (2015) Clinical implementation of cell-free DNA-based aneuploidy screening: perspectives from a national audit. Ultrasound Obstet Gynecol 45: 10–15. doi: 10.1002/uog.14699 PMID: 25323392
67. Comas C, Echevarria M, Rodriguez MA, Prats P, Rodriguez I, et al. (2014) Initial experience with non-invasive prenatal testing of cell-free DNA for major chromosomal anomalies in a clinical setting. J Matern Fetal Neonatal Med: 1–6.
68. Waitzman NJ, Romano PS, Grosse SD (2005) Half-life of cost of illness estimates: the case of spina bifida. In: Wyszynski DF, editor. Neural Tube Defects: From Origin to Treatment 1ed. USA: Oxford University Press. pp. 342–351.
69. Brewer C, Holloway S, Stone D, Carothers A, FitzPatrick D (2002) Survival in trisomy 13 and trisomy 18 cases ascertained from population based registers. Journal of Medical Genetics 39: e54–e54. PMID: 12205124
70. Wu J, Springett A, Morris JK (2013) Survival of trisomy 18 (Edwards syndrome) and trisomy 13 (Patau Syndrome) in England and Wales: 2004–2011. Am J Med Genet A 161a: 2512–2518. doi: 10.1002/ajmg.a.36127 PMID: 23949924
71. Rasmussen SA, Wong LY, Yang Q, May KM, Friedman JM (2003) Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics 111: 777–784. PMID: 12671111